<?xml version="1.0" encoding="UTF-8"?>
<p>Antiviral prophylaxis should be initiated in patients who are HBsAg-positive and/or have detectable HBV DNA before starting immunosuppressive therapyâ€”most literature specifies 7 days before [
 <xref rid="b107-ir-2019-09155" ref-type="bibr">107</xref>]. Entecavir and tenofovir are preferred to other antiviral agents, because they have high potency and a high resistance barrier, and because several meta-analyses have associated them with reduced reactivation, hepatitis, and mortality [
 <xref rid="b98-ir-2019-09155" ref-type="bibr">98</xref>,
 <xref rid="b107-ir-2019-09155" ref-type="bibr">107</xref>-
 <xref rid="b109-ir-2019-09155" ref-type="bibr">109</xref>]. The antiviral prophylaxis is recommended to be administered 6 to 12 months after discontinuation of immunosuppression [
 <xref rid="b107-ir-2019-09155" ref-type="bibr">107</xref>], as HBV reactivation beyond 12 months reported, particularly in patients who received rituximab (antiCD20 antibody) [
 <xref rid="b110-ir-2019-09155" ref-type="bibr">110</xref>-
 <xref rid="b112-ir-2019-09155" ref-type="bibr">112</xref>].
</p>
